尿毒症患者大肠杆菌的紫外线、硫酸二乙酯复合诱变
摘要
目的
用紫外线(UA)及硫酸二乙酯(DES)复合诱变的方法提高尿毒症患者肠道大肠杆菌降解尿素、肌酐的能力,为慢性肾衰的消化道细菌疗法提供新菌种。
方法
1.从慢性肾衰患者消化道中分离出大肠杆菌,鉴定及初步测试有无致病性;
2.测定尿毒症患者大肠杆菌对尿素、肌酐的基础降解能力,与正常大肠杆菌做对照;
3.诱变:测出尿毒症患者大肠杆菌生长曲线→确定生长对数期→确定紫外线对大肠杆菌的作用时间及强度→制备菌悬液→紫外线诱变处理→稀释菌液涂置筛选平板培养→收集菌悬液,检测对尿素、肌酐的降解能力→选择能使尿素或者肌酐溶液浓度下降的菌株复筛→选择能使尿素或者肌酐溶液浓度下降幅度最大的菌株扩增→确定生长对数期→以硫酸二乙酯诱变(诱变过程同紫外线诱变过程)→复筛后检测细菌稳定性。
结果
1.从尿毒症患者消化道中分离出比较纯的大肠杆菌,初步鉴定推测无致病性;
2.尿毒症患者大肠杆菌的尿素+肌酐溶液的残余浓度有所下降,但无统计学意义;
3.经过紫外线及硫酸二乙酯复合诱变后,筛选出一株对尿素、肌酐降解能力明显提高的菌株,其降解尿素的能力提高了约32.5%、降解肌酐的能力提高了约7.5%;
4.经过反复传代培养后,诱变后尿毒症大肠杆菌降解尿素、肌酐能力的稳定性欠佳。
结论
1.从尿毒症患者中分离出一株非致病性的大肠杆菌,对尿素、肌酐有一定降解作用;
2.该株大肠杆菌通过紫外线及硫酸二乙酯复合诱变育种后,其降解尿素、肌酐的能力明显增强,但其稳定性有待提高。
Objective:
Using reunion mutagenesis of ultraviolate rays and diethyl sulfate to elevate urea and creatinine degrading ability of Ecoli from intestinal tract of patient with uremia , accordingly provide new strain for the entero-bacteria therapy of chronic renal failure.
Methods:
1. Isolate Ecoli from enterobacteria of patient with chronic renal failure,assess and test if there is pathogenicity.
2. Determine basic ability of degrading urea and creatinine about Ecoli from uremic patient's intestinal tract, compared to normal Ecoli.
3. Mutagenesis:make growth curve of the Ecoli from the intestinal tract of the patient with uremia→definite growth logarithmic phase→determine the action time and intensity of ultraviolet rays( UA rays)→prepare Ecoli suspension→ultraviolet mutation→dilute the bacteria suspension and cultivate on the screening plate→detect urea and creatine degrading ability of the screening bacteria suspension→repeat screening the bacteria which can decrease the creatine concentration in uremic patient circulation→Amplificate the strain which obtain maximum decrease in the concentration of the urea and creatinine solution after degrading→definite growth logarithmic phase→diethyl sulfate mutation(the induction of mutation process is the same to the uv mutation )→repeat screening and then investigate the stability of thescreening bacteria.
Result:
1. Isolate pure Ecoli from the uremic patient intestinal tract,presume no pathogenicity through initial asess and test.
2. There is decrease which has no statistical significance in the residual concentration of the urea and creatinine degraded by Ecoli from intestinal tract of patient with uremia.
3. Reunion mutagenesis of ultraviolate rays and diethyl sulfate to the Ecoli from the intestinal tract of the patient with uremia elevate about 32.5% of the urea degrading ability and about 7.5% of the creatine degrading ability;
4. Repeatedly serial subcultivation,the stability of the urea and creatinine degrading ability about the screening strain is below the mark.
Conclusion:
1. Isolate a no pathogenicity Ecoli from enterobacteria of patient with chronic renal failure,and it has some ability of degrading urea and creatinine.
2.The Ecoli from enterobacteria of patient with chronic renal failure with obviously elevated ability of degrading urea and creatinine was screened after reunion mutagenesis of ultraviolate rays and diethyl sulfate., but the stability of the Ecoli after mutagenesis needs elevation.
用紫外线(UA)及硫酸二乙酯(DES)复合诱变的方法提高尿毒症患者肠道大肠杆菌降解尿素、肌酐的能力,为慢性肾衰的消化道细菌疗法提供新菌种。
方法
1.从慢性肾衰患者消化道中分离出大肠杆菌,鉴定及初步测试有无致病性;
2.测定尿毒症患者大肠杆菌对尿素、肌酐的基础降解能力,与正常大肠杆菌做对照;
3.诱变:测出尿毒症患者大肠杆菌生长曲线→确定生长对数期→确定紫外线对大肠杆菌的作用时间及强度→制备菌悬液→紫外线诱变处理→稀释菌液涂置筛选平板培养→收集菌悬液,检测对尿素、肌酐的降解能力→选择能使尿素或者肌酐溶液浓度下降的菌株复筛→选择能使尿素或者肌酐溶液浓度下降幅度最大的菌株扩增→确定生长对数期→以硫酸二乙酯诱变(诱变过程同紫外线诱变过程)→复筛后检测细菌稳定性。
结果
1.从尿毒症患者消化道中分离出比较纯的大肠杆菌,初步鉴定推测无致病性;
2.尿毒症患者大肠杆菌的尿素+肌酐溶液的残余浓度有所下降,但无统计学意义;
3.经过紫外线及硫酸二乙酯复合诱变后,筛选出一株对尿素、肌酐降解能力明显提高的菌株,其降解尿素的能力提高了约32.5%、降解肌酐的能力提高了约7.5%;
4.经过反复传代培养后,诱变后尿毒症大肠杆菌降解尿素、肌酐能力的稳定性欠佳。
结论
1.从尿毒症患者中分离出一株非致病性的大肠杆菌,对尿素、肌酐有一定降解作用;
2.该株大肠杆菌通过紫外线及硫酸二乙酯复合诱变育种后,其降解尿素、肌酐的能力明显增强,但其稳定性有待提高。
Objective:
Using reunion mutagenesis of ultraviolate rays and diethyl sulfate to elevate urea and creatinine degrading ability of Ecoli from intestinal tract of patient with uremia , accordingly provide new strain for the entero-bacteria therapy of chronic renal failure.
Methods:
1. Isolate Ecoli from enterobacteria of patient with chronic renal failure,assess and test if there is pathogenicity.
2. Determine basic ability of degrading urea and creatinine about Ecoli from uremic patient's intestinal tract, compared to normal Ecoli.
3. Mutagenesis:make growth curve of the Ecoli from the intestinal tract of the patient with uremia→definite growth logarithmic phase→determine the action time and intensity of ultraviolet rays( UA rays)→prepare Ecoli suspension→ultraviolet mutation→dilute the bacteria suspension and cultivate on the screening plate→detect urea and creatine degrading ability of the screening bacteria suspension→repeat screening the bacteria which can decrease the creatine concentration in uremic patient circulation→Amplificate the strain which obtain maximum decrease in the concentration of the urea and creatinine solution after degrading→definite growth logarithmic phase→diethyl sulfate mutation(the induction of mutation process is the same to the uv mutation )→repeat screening and then investigate the stability of thescreening bacteria.
Result:
1. Isolate pure Ecoli from the uremic patient intestinal tract,presume no pathogenicity through initial asess and test.
2. There is decrease which has no statistical significance in the residual concentration of the urea and creatinine degraded by Ecoli from intestinal tract of patient with uremia.
3. Reunion mutagenesis of ultraviolate rays and diethyl sulfate to the Ecoli from the intestinal tract of the patient with uremia elevate about 32.5% of the urea degrading ability and about 7.5% of the creatine degrading ability;
4. Repeatedly serial subcultivation,the stability of the urea and creatinine degrading ability about the screening strain is below the mark.
Conclusion:
1. Isolate a no pathogenicity Ecoli from enterobacteria of patient with chronic renal failure,and it has some ability of degrading urea and creatinine.
2.The Ecoli from enterobacteria of patient with chronic renal failure with obviously elevated ability of degrading urea and creatinine was screened after reunion mutagenesis of ultraviolate rays and diethyl sulfate., but the stability of the Ecoli after mutagenesis needs elevation.
引文
1.Ranganathan,Natarejan;Patel,BeenaG;Ranganathan,Pari;Marczely,Joseph;Dheer,Ra hul;Pechenyak,Bohdan;Dunn,StephenR;Verstraere,Willy;Decroos,Karel;Mehta,Raj;Friedman,Eli A.Invitro and invivo assessement of intraintestinal bacteriotherapy in chronic kidmey disease[J].Amercian Society of Artifical Internal Organs.2006,52(1).70-79.
2 李晓玫,慢性肾脏病的一体化防治的理念于目标[J],临床内科杂志,2005,22(11):291-292,
3 高虹;俞耀庭;蔡宝立.微囊化基因工程菌作为尿毒症口服制剂的研究[J].科学通报,2004;498-499
4 刘广桢;陈建华;王曼.尿酸酶产生菌的筛选基因克隆及表达[J].中国药科大学学,2005,3q5):464-466
5.高虹;陈明;郑津辉.医用尿酸酶菌的分离与选育[J]天津师范大学报,2003,9;23(3).231-234
6.Sucuki k,Benno Y,Mitsuoka T,et al.Urease-producing species of intestnal anaerobes and their activities[J].Appl Environ Microbiol,1979,37:379-382
7 Chow KM,Liu ZC,Chang TMS,Free and microencapaulated lactobacillus and effcts of metabolic induction on urea removel[J].Art Cekks&Immob Biotech.2003,31(4):425-434.
8.O'Loughlin JA,Bruder JM,Lysaght,et al.Degardation of Low Molecular Weight uremic solutes by oral delivery of en capsulated enzymes[J].Amenrcian Society of Artificial Internal Organs,2004,50(3):253-260.
9 Gu KF,Chang TM..Conversion of ammonia or urea into essential amino acids,L-leucine,L-valine,and L-isoleucine,using artificial cells containing an immobilized multienzyme system and dextran-NAD+.2.Yeast alcohol dehydrogenase for coenzyme recycling.[J]Biotechnol Appl Biochem.1990Jun;12(3):227-36.
10.Chang TMS,Malouf C,Rensurreccion E.Atificial cells mircroencapsulated multienzyme system for converting urea and ammonia to amino acid using alpha-ketoglutarate and glucose sa substrate[J].Trans Am Soc Artif Intern Organs,1978,24:18-20.
11.Brown CL,Hill MJ,Richards P.Bacterial ureases in uraemic men[J].Lancet,1971,2:406-408.
12.Hida M,Aiba Y,Sawamura S,et al.Inhibition of the accumuliation of uremic toxins in the blood and their precursors in the fecse after oral administration of Lebenin,a lactic acid bacteria preparation,to uremic patients undergoing hemodiaysis [J].Nephron.1996;74(2):349-355
13.Ando Y,Miyata Y,Tanba K,et al.Effeet of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure[J].Nippon Jinzo GakkaiShi.2003:45(8):459-64.
14.Takayama F,Taki K,Niwa T.Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis[J].Am J Kidney Dis,2003;41(3)Suppl 1:S142-5.
15.宋尚明,周生芬,郑功泉等。慢性肾功能衰竭患者肠道微生态变化及微生态制剂疗效观察[J].内科急危重症杂志;2001,7(2):71-82。
16.Ranganathan N,Patel BG,Ranganathan P,et al.In vitro and in vivo assessment of intraintestinal bacteriotherapy in.chronic kidney disease[J],ASAIO Journal.2006,52(1)70-79.
17.焦闻文,将云生.保伽利亚乳杆菌对尿素、肌酐降解能力的定向诱导与诱变[D],中南大学学报,2007.10:35-38
18.Prakash S,Chang TM..Genetically engineered E.coli cells containing K.aerogenes gene,microencapsulated in artificial cells for urea and ammonia removal.[J]Biomater Artif Cells Immobilization Biotechnol,1993,21(5):629-36,
19.Prakash S,Chang TM.Microencapsulated genetically engineered E.coli DH5 cells for plasma urea and ammonia removal based on:1.Column bioreactor and 2.Oral administration in uremic rats[J].Artif Cells Blood Substit Immobil Biotechnol,1996,24(3):201-18,
20.Prakash S,Chang TM.Microencapsulated genctically engineered live E.coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats.[J]Nat Med,1996,2(8):883-7,
21.Chang TM,Prakash S.Artificial cells for bioencapsulation of cells and genetically engineered E.coli.For cell therapy,gene therapy,and removal of urea and ammonia[J].Methods Mol Biol,1997,63:343-58,
21.Prakash S,Chang TM.Growth kinetics of genetically engineered E.coli DH 5 cells in artificial cell APA membrane microcapsules:preliminary report.[J]Artif Cells Blood Substit Irnmobil Biotechnol,1999,27(3):291-301.
23.Prakash S,Chang TM..In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineered E.coli DH5 cells[J].Int J Artif Organs,2000,23(7):429-35,
24.Prakash S,Chang TM..Artificial cells microencapsulated genetically engineered E.coli DH5 cells for the lowering of plasma creatinine in-vitro and in-vivo[J].Artif Cells Blood Substit Immobil Biotechnol,2000,28(5):397-408,
25.Chang TM,.Prakash S.Procedures for microencapsulation of enzymes,cells and genetically engineered microorganisms[J].Mol Biotechnol,2001,17(3):249-60,
26.Chow KM,Liu ZC,Prakash S,Chang TM..Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal[J].Artif Cells Blood Substit Immobil Biotechnol,2003,31(4):425-34,
27.Prakash S,Chang TM.Artificial cell microcapsules containing genetically engineered E.coli DH5 cells for in-vitro lowering of plasma potassium,phosphate,magnesium,sodium,chloride,uric acid,cholesterol,and creatinine:a preliminary report[J].Artif Cells Blood Substit Immobil Biotechnol,1999,27(5-6):475-81,
28.Prakash S,Chang TM.Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E.coli DH5 cells for urea removal[J].Artif Cells Blood Substit Immobil Biotechnol,1998,26(1):35-51,
29 陈立平,蒋云生,罗季安.慢性肾衰患者尿毒素对肠道细菌的作用[J].湖南医科大学学报,1999,24(2):183-185.
30.周建琴,韩宝玲,王南金等.康乐霉素C产生菌的诱变育种及其发酵的研究 [J].中国抗生素杂志,2000,25(5):386-387
31.王筱虹等,原生质体紫外诱变技术筛选红霉素高产菌株的研究[J]中国药科大学学报,2000,31(4):301-303.
32.Ibrahim SA,O'Sullivan DJ.Use of chemical muragenesis for the isolation of food grade beta-galactosidase overproducing mutans of bifidobacteria,lactobacilli and Streptococcus thermophilus[J],J Dairy Sci,2000,83(5):923-930.
33.迟乃玉,刘英吴,张庆芳等.SOD高产菌株乳酸菌的选育及其产酶条件的研究[J].微生物通报。2001,28(6):22-25。
1. Bottomley WK, Cioffi RF, Martin AJ. Dental management of the patient treated by renal transplantation: preoperative and postoperative considerations[J]. Am Dent Assoc 1972;85:1330-1335.
2. Naylor GD, Fredericks MR. Pharmacologic considerations in the dental management of the patient with disorders of the renal system[J]. Dent Clin North Amer 1996;40:665-683
3. Heard E Jr, Staples AF, Czerwinski AW. The dental patients with renal disease. Precautions and guidelines[J]. J Am Dent Assoc 1978;96:792-796.
4. Kho H, Lee S, Cheng S, Kim Y. Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing hemodialysis[J]. Oral surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 316-319.
5. Klassen JT, Krasko BM. The dental health status of dialysis patients[J]. Can Dent Assoc 2002;68:34-38.
6. Frankenthal S, Nakhoul F, Machtei EE, Green J, Ardekian L, Laufer D, Peled M. The effect of secondary hyperparathyroidism and hemodialysis therapy on alveolar bone and periodontium[J]. Clin Periodontol 2002;29:479-483.
7. Gavalda C, Bagan JV, Scully C, Silvestre FJ, Milian MA, Jimenez. Renal hemodialysis patients: oral, salivary, dental and periodontal findings in 105 adult cases[J]. Oral Dis 1999;5:299-302.
8. Wilson TG, Kornman KS. Fundamentals of periodontics. 2nd ed. Chicago[M]: Quintessence Publishing Co.; 2003.5:215-18
9. Jair C. Leao; Luiz Alcino M. Gueiros; Airton V. Leite Segundo; Alessandra A. T. Carvalho; Willian Barrett; Stephen R. Porter. Uremic stomatitis in chronic renal failure[J].Clinics.2005;60(3):259-62.
10. Ravelli, S.E. Ledermann and W.M. Bisset et al., Foregut motor function in chronic renal failure[J],Arch Dis Child. 1992, 67: 1343-1347.
11. Ravelli, Gastrointestinal function in chronic renal failure[J], Pediatr Nephrol 1995, 9:756-762.
12.M.Tugay,F.Yildiz and T.Utkan et al.,Esophagitis impairs esophageal smooth muscle reactivity in the rat model:an in vitro study[J],Dig Dis Sci.2003 48:2147-2152.
13..Yildiz F,Tugay M,Utkan T,Yazir Y et al.Effect of chronic renal failure on foregut smooth muscle reactivity:an experimental study[J].Pediatr Surg,2007,42(4):647-52,
14.单慧明 王菊梅 等.尿毒症合并表层剥脱性食管炎一例[J]。中华内科杂志,2002,41(8):512-512
15.Devarbhavi H,Alvares JF.Esophagitis dessicans superficialis with bulla in chronic renal failure:a case report[J].Gastrointest Endosc.2001,54(2):256-8
16.曾西,蒋云生。尿毒症患者胃肠道改变[J]。国外医学泌尿系统分册。2004,24(2):265-268.
17.Emirs,Bertcket G,Boyaeioglu S,et al.Gasatronestinal lessions and Helioobacte pylori in children with end-stage renal disease[J].Pediatr Nehrd.2000,14(9),837-840
18.Karari EM,Lule GN,McLigeyo SO,Amayo EO.Endoscopic findings and the prevalence of Helicobacter pylori in chronic renal failure patients with dyspepsia[J].East Afr Med J.2000;77(8):406-9.
19.R.Sotoudehmanesh~1,A.AliAsgari~1,R.Ansari~1,M.Nouraieo Gastroduodenal lesions and Helicobacter pylori infection in hemodialysis patients[J].Saudi Med J.2004 Aug;25(8):1010-4.
20.Khedmat H,Ahmadzad-Asl M,Amini M,Lessan-Pezeshki M,Einollahi B,Pourfarziani V,Naseri MH,Davoudi F.Gastro-Duodenal Lesions and Helicobacter pylori Infection in Uremic Patients and Renal Transplant Recipients[J].Transplant Proc.2007 May;39(4):1003-7.
21.E.M.Karari,G.N.Lule and S.O.McLigeyo et al.,Endoscopic findoing and prevalence of Helicobacter pylori in chronic renal failure patients with dyspepsia[J],East Afr Med J 2000,77:406.
22.G.C.Marrone and W.Silen,Pathogenesis,diagnosis and treatment of acute gastric mucosai lesions[J],Clin Gastroentrol 13(1984),635-39.
23.A.Abu-saif and J.H.Lewis,Gastrointestinal and hepatic disorders in ens-stage renal disease and renal transplant recipients[J],Adv Ren Replace Ther 7(2000),220-24.
24.F.Fabbian,C.Catalano and V.Bordin et al.,Esophagogastroduo- denoscopy in chronic hemodialysis patients:2-year clinical experience in a renal unit[J],Clin Nephrol 58(2002),p.54.
25.方一卿.慢性肾衰病血液透析患者的胃肠肽激素变化[J].国外医学泌尿系统分册,2000,20(2):85-86.
26.崔泽忠,李友芸,易刚,等.慢性肾功能不全患者胃电图的变化[J].泸州医学院学报,1999,22(6):493-494.
27.TomomasaT,Morikawa A,salldkx RH,et al.Gastroitestinal sounds and migrating motor complex infasted humans[J].Am JGasreoenterol,1999,94(2):374-381.
28.黄雯,万小平,张建忠,等.尿毒症患者消化间期移行性复合运动规律的化[J].肾脏病与透析移植杂志,2001,10(5):445-446.
29.张金黎,赵石,罗惠民,等.慢性肾功能衰竭患者消化道运动功能研究[J].中华.肾脏病杂志,2000,16(6):401-402.
30.王海燕.肾脏病学[M].第2版.北京:人民卫生出版社,1998.1393.
31.Bjornsson ES,Abrahamsson H:Contractile patterns in patients with severe chronic dyspepsia[J].Am J Gastroenterol 1999;94:54-64
32.Kellow JE,Gill RC,Wingate DL:Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome[J].Gastroenterology 1990;98:1208-1218.
33.Simrén M,Castedal M,Svedlund J,Abrahamsson H,Bjrrnsson E:Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS)[J].Dig Dis Sci 2000;45:2151-2161.
34.Madrid AM,Hurtado C,Venegas M,Cumsille F,Defilippi C:Long-term treatment with cisapride and antibiotics in liver cirrhosis:Effect on small intestinal motility,bacterial overgrowth,and liver function[J].Am J Gastroenterol 2001;96:1251-1255.
35.Lefebvre HP,Ferre JP,Watson AD,Brown CA,Serthelon JP,Laroute V,et al:Small bowel motility and colonic transit are altered in dogs with moderate renal failure[J].Am J Physiol 2001;281:R230-238.
36.Strid H,Simrén M,Stotzer PO,Ringstrom G,Abrahamsson H,Bjornsson ES Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth[J].Digestion,67(3):129-37,2003
37.Etemad B.Gastrointestinal complications of renal failure[J].Gastroenterol Clin North Am 1998;27:875-892
38.Kang JY.The gastrointestinal tract in uremia[J].Dig Dis Sci 1993;38:257-268.
39.Akmal M,Sawelson S,Karubian F,Gadallah M.The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF),or receiving dialytic therapy[J].Clin Nephrol 1994;42:365-69
40.Stephanos Karagiannis,Spyros Goulas,Georgios Kosmadakis,Petros Galanis,Dimitrios Arvanitis,John Boletis,Evangelos Georgiou,Christos Mavrogiannis.Wireless capsule endoscopy in the investigation of patients with chronic renal failure and obscure gastrointestinal bleeding(preliminary data)[J].World J Gastroenterol 2006 July 28;12(32):5182-5185.
41.Evaldson.The normal human anaerobic microflora[J].Scand J Infect Dis,1982,35(Suppl):9-15.
42.Bobrov VA,Karpov PF.Microecological disorders in the intestines of patients with chronic kidney failure and the arterial hypertension syndrome[J].Ter Arkh.1993;65(6):41-3.
43.Setala K.Bacterial enzymes in uremia management[J].Kidney Int,1978,13:5194-202.
44.陈玉龙,王耀芝主编.消化系统疾病诊断治疗新进展.第一版[M],科学技术文献出版社,1995:39-50.
45.郁庆福主编.现代卫生微生物学[M].第一版,北京:人民卫生出版社出版,1995:67-68.
46.Berkes J,Wiswanathan VK,Savkovic SD,etal.Intestinal epithelial responses to enteric pathogens: effect on the tight junction barriers, ion transport and inflammation[J]. Gut,2003,52(3),439-51.
2 李晓玫,慢性肾脏病的一体化防治的理念于目标[J],临床内科杂志,2005,22(11):291-292,
3 高虹;俞耀庭;蔡宝立.微囊化基因工程菌作为尿毒症口服制剂的研究[J].科学通报,2004;498-499
4 刘广桢;陈建华;王曼.尿酸酶产生菌的筛选基因克隆及表达[J].中国药科大学学,2005,3q5):464-466
5.高虹;陈明;郑津辉.医用尿酸酶菌的分离与选育[J]天津师范大学报,2003,9;23(3).231-234
6.Sucuki k,Benno Y,Mitsuoka T,et al.Urease-producing species of intestnal anaerobes and their activities[J].Appl Environ Microbiol,1979,37:379-382
7 Chow KM,Liu ZC,Chang TMS,Free and microencapaulated lactobacillus and effcts of metabolic induction on urea removel[J].Art Cekks&Immob Biotech.2003,31(4):425-434.
8.O'Loughlin JA,Bruder JM,Lysaght,et al.Degardation of Low Molecular Weight uremic solutes by oral delivery of en capsulated enzymes[J].Amenrcian Society of Artificial Internal Organs,2004,50(3):253-260.
9 Gu KF,Chang TM..Conversion of ammonia or urea into essential amino acids,L-leucine,L-valine,and L-isoleucine,using artificial cells containing an immobilized multienzyme system and dextran-NAD+.2.Yeast alcohol dehydrogenase for coenzyme recycling.[J]Biotechnol Appl Biochem.1990Jun;12(3):227-36.
10.Chang TMS,Malouf C,Rensurreccion E.Atificial cells mircroencapsulated multienzyme system for converting urea and ammonia to amino acid using alpha-ketoglutarate and glucose sa substrate[J].Trans Am Soc Artif Intern Organs,1978,24:18-20.
11.Brown CL,Hill MJ,Richards P.Bacterial ureases in uraemic men[J].Lancet,1971,2:406-408.
12.Hida M,Aiba Y,Sawamura S,et al.Inhibition of the accumuliation of uremic toxins in the blood and their precursors in the fecse after oral administration of Lebenin,a lactic acid bacteria preparation,to uremic patients undergoing hemodiaysis [J].Nephron.1996;74(2):349-355
13.Ando Y,Miyata Y,Tanba K,et al.Effeet of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure[J].Nippon Jinzo GakkaiShi.2003:45(8):459-64.
14.Takayama F,Taki K,Niwa T.Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis[J].Am J Kidney Dis,2003;41(3)Suppl 1:S142-5.
15.宋尚明,周生芬,郑功泉等。慢性肾功能衰竭患者肠道微生态变化及微生态制剂疗效观察[J].内科急危重症杂志;2001,7(2):71-82。
16.Ranganathan N,Patel BG,Ranganathan P,et al.In vitro and in vivo assessment of intraintestinal bacteriotherapy in.chronic kidney disease[J],ASAIO Journal.2006,52(1)70-79.
17.焦闻文,将云生.保伽利亚乳杆菌对尿素、肌酐降解能力的定向诱导与诱变[D],中南大学学报,2007.10:35-38
18.Prakash S,Chang TM..Genetically engineered E.coli cells containing K.aerogenes gene,microencapsulated in artificial cells for urea and ammonia removal.[J]Biomater Artif Cells Immobilization Biotechnol,1993,21(5):629-36,
19.Prakash S,Chang TM.Microencapsulated genetically engineered E.coli DH5 cells for plasma urea and ammonia removal based on:1.Column bioreactor and 2.Oral administration in uremic rats[J].Artif Cells Blood Substit Immobil Biotechnol,1996,24(3):201-18,
20.Prakash S,Chang TM.Microencapsulated genctically engineered live E.coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats.[J]Nat Med,1996,2(8):883-7,
21.Chang TM,Prakash S.Artificial cells for bioencapsulation of cells and genetically engineered E.coli.For cell therapy,gene therapy,and removal of urea and ammonia[J].Methods Mol Biol,1997,63:343-58,
21.Prakash S,Chang TM.Growth kinetics of genetically engineered E.coli DH 5 cells in artificial cell APA membrane microcapsules:preliminary report.[J]Artif Cells Blood Substit Irnmobil Biotechnol,1999,27(3):291-301.
23.Prakash S,Chang TM..In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineered E.coli DH5 cells[J].Int J Artif Organs,2000,23(7):429-35,
24.Prakash S,Chang TM..Artificial cells microencapsulated genetically engineered E.coli DH5 cells for the lowering of plasma creatinine in-vitro and in-vivo[J].Artif Cells Blood Substit Immobil Biotechnol,2000,28(5):397-408,
25.Chang TM,.Prakash S.Procedures for microencapsulation of enzymes,cells and genetically engineered microorganisms[J].Mol Biotechnol,2001,17(3):249-60,
26.Chow KM,Liu ZC,Prakash S,Chang TM..Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal[J].Artif Cells Blood Substit Immobil Biotechnol,2003,31(4):425-34,
27.Prakash S,Chang TM.Artificial cell microcapsules containing genetically engineered E.coli DH5 cells for in-vitro lowering of plasma potassium,phosphate,magnesium,sodium,chloride,uric acid,cholesterol,and creatinine:a preliminary report[J].Artif Cells Blood Substit Immobil Biotechnol,1999,27(5-6):475-81,
28.Prakash S,Chang TM.Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E.coli DH5 cells for urea removal[J].Artif Cells Blood Substit Immobil Biotechnol,1998,26(1):35-51,
29 陈立平,蒋云生,罗季安.慢性肾衰患者尿毒素对肠道细菌的作用[J].湖南医科大学学报,1999,24(2):183-185.
30.周建琴,韩宝玲,王南金等.康乐霉素C产生菌的诱变育种及其发酵的研究 [J].中国抗生素杂志,2000,25(5):386-387
31.王筱虹等,原生质体紫外诱变技术筛选红霉素高产菌株的研究[J]中国药科大学学报,2000,31(4):301-303.
32.Ibrahim SA,O'Sullivan DJ.Use of chemical muragenesis for the isolation of food grade beta-galactosidase overproducing mutans of bifidobacteria,lactobacilli and Streptococcus thermophilus[J],J Dairy Sci,2000,83(5):923-930.
33.迟乃玉,刘英吴,张庆芳等.SOD高产菌株乳酸菌的选育及其产酶条件的研究[J].微生物通报。2001,28(6):22-25。
1. Bottomley WK, Cioffi RF, Martin AJ. Dental management of the patient treated by renal transplantation: preoperative and postoperative considerations[J]. Am Dent Assoc 1972;85:1330-1335.
2. Naylor GD, Fredericks MR. Pharmacologic considerations in the dental management of the patient with disorders of the renal system[J]. Dent Clin North Amer 1996;40:665-683
3. Heard E Jr, Staples AF, Czerwinski AW. The dental patients with renal disease. Precautions and guidelines[J]. J Am Dent Assoc 1978;96:792-796.
4. Kho H, Lee S, Cheng S, Kim Y. Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing hemodialysis[J]. Oral surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 316-319.
5. Klassen JT, Krasko BM. The dental health status of dialysis patients[J]. Can Dent Assoc 2002;68:34-38.
6. Frankenthal S, Nakhoul F, Machtei EE, Green J, Ardekian L, Laufer D, Peled M. The effect of secondary hyperparathyroidism and hemodialysis therapy on alveolar bone and periodontium[J]. Clin Periodontol 2002;29:479-483.
7. Gavalda C, Bagan JV, Scully C, Silvestre FJ, Milian MA, Jimenez. Renal hemodialysis patients: oral, salivary, dental and periodontal findings in 105 adult cases[J]. Oral Dis 1999;5:299-302.
8. Wilson TG, Kornman KS. Fundamentals of periodontics. 2nd ed. Chicago[M]: Quintessence Publishing Co.; 2003.5:215-18
9. Jair C. Leao; Luiz Alcino M. Gueiros; Airton V. Leite Segundo; Alessandra A. T. Carvalho; Willian Barrett; Stephen R. Porter. Uremic stomatitis in chronic renal failure[J].Clinics.2005;60(3):259-62.
10. Ravelli, S.E. Ledermann and W.M. Bisset et al., Foregut motor function in chronic renal failure[J],Arch Dis Child. 1992, 67: 1343-1347.
11. Ravelli, Gastrointestinal function in chronic renal failure[J], Pediatr Nephrol 1995, 9:756-762.
12.M.Tugay,F.Yildiz and T.Utkan et al.,Esophagitis impairs esophageal smooth muscle reactivity in the rat model:an in vitro study[J],Dig Dis Sci.2003 48:2147-2152.
13..Yildiz F,Tugay M,Utkan T,Yazir Y et al.Effect of chronic renal failure on foregut smooth muscle reactivity:an experimental study[J].Pediatr Surg,2007,42(4):647-52,
14.单慧明 王菊梅 等.尿毒症合并表层剥脱性食管炎一例[J]。中华内科杂志,2002,41(8):512-512
15.Devarbhavi H,Alvares JF.Esophagitis dessicans superficialis with bulla in chronic renal failure:a case report[J].Gastrointest Endosc.2001,54(2):256-8
16.曾西,蒋云生。尿毒症患者胃肠道改变[J]。国外医学泌尿系统分册。2004,24(2):265-268.
17.Emirs,Bertcket G,Boyaeioglu S,et al.Gasatronestinal lessions and Helioobacte pylori in children with end-stage renal disease[J].Pediatr Nehrd.2000,14(9),837-840
18.Karari EM,Lule GN,McLigeyo SO,Amayo EO.Endoscopic findings and the prevalence of Helicobacter pylori in chronic renal failure patients with dyspepsia[J].East Afr Med J.2000;77(8):406-9.
19.R.Sotoudehmanesh~1,A.AliAsgari~1,R.Ansari~1,M.Nouraieo Gastroduodenal lesions and Helicobacter pylori infection in hemodialysis patients[J].Saudi Med J.2004 Aug;25(8):1010-4.
20.Khedmat H,Ahmadzad-Asl M,Amini M,Lessan-Pezeshki M,Einollahi B,Pourfarziani V,Naseri MH,Davoudi F.Gastro-Duodenal Lesions and Helicobacter pylori Infection in Uremic Patients and Renal Transplant Recipients[J].Transplant Proc.2007 May;39(4):1003-7.
21.E.M.Karari,G.N.Lule and S.O.McLigeyo et al.,Endoscopic findoing and prevalence of Helicobacter pylori in chronic renal failure patients with dyspepsia[J],East Afr Med J 2000,77:406.
22.G.C.Marrone and W.Silen,Pathogenesis,diagnosis and treatment of acute gastric mucosai lesions[J],Clin Gastroentrol 13(1984),635-39.
23.A.Abu-saif and J.H.Lewis,Gastrointestinal and hepatic disorders in ens-stage renal disease and renal transplant recipients[J],Adv Ren Replace Ther 7(2000),220-24.
24.F.Fabbian,C.Catalano and V.Bordin et al.,Esophagogastroduo- denoscopy in chronic hemodialysis patients:2-year clinical experience in a renal unit[J],Clin Nephrol 58(2002),p.54.
25.方一卿.慢性肾衰病血液透析患者的胃肠肽激素变化[J].国外医学泌尿系统分册,2000,20(2):85-86.
26.崔泽忠,李友芸,易刚,等.慢性肾功能不全患者胃电图的变化[J].泸州医学院学报,1999,22(6):493-494.
27.TomomasaT,Morikawa A,salldkx RH,et al.Gastroitestinal sounds and migrating motor complex infasted humans[J].Am JGasreoenterol,1999,94(2):374-381.
28.黄雯,万小平,张建忠,等.尿毒症患者消化间期移行性复合运动规律的化[J].肾脏病与透析移植杂志,2001,10(5):445-446.
29.张金黎,赵石,罗惠民,等.慢性肾功能衰竭患者消化道运动功能研究[J].中华.肾脏病杂志,2000,16(6):401-402.
30.王海燕.肾脏病学[M].第2版.北京:人民卫生出版社,1998.1393.
31.Bjornsson ES,Abrahamsson H:Contractile patterns in patients with severe chronic dyspepsia[J].Am J Gastroenterol 1999;94:54-64
32.Kellow JE,Gill RC,Wingate DL:Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome[J].Gastroenterology 1990;98:1208-1218.
33.Simrén M,Castedal M,Svedlund J,Abrahamsson H,Bjrrnsson E:Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS)[J].Dig Dis Sci 2000;45:2151-2161.
34.Madrid AM,Hurtado C,Venegas M,Cumsille F,Defilippi C:Long-term treatment with cisapride and antibiotics in liver cirrhosis:Effect on small intestinal motility,bacterial overgrowth,and liver function[J].Am J Gastroenterol 2001;96:1251-1255.
35.Lefebvre HP,Ferre JP,Watson AD,Brown CA,Serthelon JP,Laroute V,et al:Small bowel motility and colonic transit are altered in dogs with moderate renal failure[J].Am J Physiol 2001;281:R230-238.
36.Strid H,Simrén M,Stotzer PO,Ringstrom G,Abrahamsson H,Bjornsson ES Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth[J].Digestion,67(3):129-37,2003
37.Etemad B.Gastrointestinal complications of renal failure[J].Gastroenterol Clin North Am 1998;27:875-892
38.Kang JY.The gastrointestinal tract in uremia[J].Dig Dis Sci 1993;38:257-268.
39.Akmal M,Sawelson S,Karubian F,Gadallah M.The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF),or receiving dialytic therapy[J].Clin Nephrol 1994;42:365-69
40.Stephanos Karagiannis,Spyros Goulas,Georgios Kosmadakis,Petros Galanis,Dimitrios Arvanitis,John Boletis,Evangelos Georgiou,Christos Mavrogiannis.Wireless capsule endoscopy in the investigation of patients with chronic renal failure and obscure gastrointestinal bleeding(preliminary data)[J].World J Gastroenterol 2006 July 28;12(32):5182-5185.
41.Evaldson.The normal human anaerobic microflora[J].Scand J Infect Dis,1982,35(Suppl):9-15.
42.Bobrov VA,Karpov PF.Microecological disorders in the intestines of patients with chronic kidney failure and the arterial hypertension syndrome[J].Ter Arkh.1993;65(6):41-3.
43.Setala K.Bacterial enzymes in uremia management[J].Kidney Int,1978,13:5194-202.
44.陈玉龙,王耀芝主编.消化系统疾病诊断治疗新进展.第一版[M],科学技术文献出版社,1995:39-50.
45.郁庆福主编.现代卫生微生物学[M].第一版,北京:人民卫生出版社出版,1995:67-68.
46.Berkes J,Wiswanathan VK,Savkovic SD,etal.Intestinal epithelial responses to enteric pathogens: effect on the tight junction barriers, ion transport and inflammation[J]. Gut,2003,52(3),439-51.